Table 2.

Immunophenotypic Characteristics

Characteristics	All ROS1 Fusion Patients N = 184	Immunophenotypic Cohort n = 145	ICI Cohort n = 28	Chemo-ICI Cohort n = 11
Tumor PD-L1 expression
# of patients	146	119	17	10
Median (range)	8 (0–100)	1 (0–100)	70 (0–90)	38 (0–90)
<1%	60 (41)	56 (47)	3 (18)	1 (10)
1%–49%	35 (24)	28 (24)	3 (18)	4 (40)
≥50%	51 (35)	35 (29)	11 (65)	5 (50)
TMB (mut/Mb)
# of patients	100	77	16	7
Median (range)	3 (0–20)	3 (0–20)	3 (1–20)	2 (1–5)
<5	68 (68)	51 (66)	12 (75)	5 (71)
5–9	24 (24)	20 (26)	2 (13)	2 (29)
≥10	8 (8)	6 (8)	2 (13)	0 (0)

Note: # of patients refers to the number of patients in which PD-L1 or TMB, respectively, was available.

Chemo-ICI, chemotherapy with immune checkpoint inhibitor; ICI, immune checkpoint inhibitor; mut/mb, mutations per megabase; PD-L1, programmed death-ligand 1; TMB, tumor mutational burden.